Evidence map›Paper›PMID 41504999›Full record

ReviewJournal of applied genetics2026

Epstein-barr virus and multiple sclerosis: from pathogenesis and diagnosis to EBV-specific T cell therapy and gene-targeted therapeutics.

Mukesh Pushkarna, Ahmed Zwamel, Seema Verma, H Malathi, Mukhlisa Mustafayeva, Harpreet Kaur, Ali M Ali Al-Nuaimi, Beneen Husseen, Mohammad Dahghani

Abstract readReview
PubMed Publisher
In one paragraph

Review in Journal of applied genetics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Mukesh PushkarnaFaculty of Pharmacy, Gokul Global University, Sidhpur, Gujarat, India.
Ahmed ZwamelDepartment of medical analysis, Medical laboratory technique college, The Islamic University, Najaf, Iraq.
Seema VermaDepartment of Biotechnology and Genetics, Jain (Deemed-to-be) University, Bengaluru, Karnataka, 560069, India.
H MalathiSharda School of Pharmacy, Sharda University, Greater Noida, UP, India.
Mukhlisa MustafayevaDepartment of psychology, Mamun university, Khiva, Uzbekistan.
Harpreet KaurSchool of Basic & Applied Sciences, Shobhit University, Gangoh, Uttar Pradesh, 247341, India.
Ali M Ali Al-NuaimiGilgamesh Ahliya University, Baghdad, Iraq.
Beneen HusseenCentre for Research Impact & Outcome, Chitkara University Institute of Engineering and Technology, Chitkara University, Rajpura, 140401, Punjab, India.
Mohammad DahghaniHematology-Oncology Department, Imam Reza Educational Hospital, Islamic Azad University of Medical Sciences, Tehran, Iran. rasuli.mohammad1992@gmail.com.ORCID http://orcid.org/0000-0001-7272-3804

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Multiple sclerosis (MS) is a central nervous system (CNS) disorder defined by inflammation, demyelination, and neuronal damage. Several independent studies have confirmed the prevalence of EBV infection in MS and the presence of elevated anti-EBV antibody titers in serum prior to and throughout the clinical period of MS. EBV stands out from other human-infecting viruses in that it can activate, infect, and clone the B cells and remain a latent infection inside them. The prevalence of EBV-positive B cell lymphoproliferative diseases in immunocompromised individuals demonstrates the critical significance of immune surveillance in managing EBV infection. It has also been postulated that a deficiency in EBV-specific CD8

Indexed as

Anti-EBV immunityEBNA1EBV-specific t-cell therapyMultiple sclerosis

Identifiers

PMID41504999

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.